Cessation of 2 Independent Directors on Tenure Completion.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has informed the stock exchanges that two of its Independent Directors, Mr. Aspi Navroze Raimalwala and Mr. Rohinton Adi Kanga, retired from the board after completing their second term. Their cessation was effective from the close of business on September 29, 2025. The company filed this disclosure under SEBI's Listing Regulations, attaching the required Annexure-I with director details. The Managing Director, Fredun Nariman Medhora, signed the filing. No reasons beyond tenure completion have been flagged, and there is no indication of any governance concerns or disputes.
This is a routine, planned board change with no negative signal — the stock price is unlikely to be affected. Shareholders should watch for timely appointment of new Independent Directors to ensure the board remains compliant with listing rules.